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ABSTRACT
Hypertrophic scars arise when there is an overproduction of collagen during wound healing. These are often
associated with poor regulation of the rate of programmed cell death (apoptosis) of the cells synthesizing the
collagen or by an exuberant inflammatory response that prolongs collagen production and increases wound
contraction. Severe contractures that occur, for example, after a deep burn can cause loss of function especially
if the wound is over a joint such as the elbow or knee. Recently, we have developed a morphoelastic mathematical
model for dermal repair that incorporates the chemical, cellular and mechanical aspects of dermal wound healing.
Using this model, we examine pathological scarring in dermal repair by first assuming a smaller than usual
apoptotic rate for myofibroblasts, and then considering a prolonged inflammatory response, in an attempt to
determine a possible optimal intervention strategy to promote normal repair, or terminate the fibrotic scarring
response. Our model predicts that in both cases it is best to apply the intervention strategy early in the wound
healing response. Further, the earlier an intervention is made, the less aggressive the intervention required.
Finally, if intervention is conducted at a late time during healing, a significant intervention is required; however,
there is a threshold concentration of the drug or therapy applied, above which minimal further improvement to
wound repair is obtained.
INTRODUCTION
Dermal wound healing is a complex process in which the final product, scar tissue, is inferior to unwounded
dermis. In 5−15% of all wounds, dysregulation in the repair process occurs, giving rise to pathological outcomes
2including hypertrophic scars, contractures and keloids1. This represents a significant problem, particularly for
surgeons and other clinicians where up to 94% of surgical wounds and up to 91% of burn injuries may heal with
scar hypertrophy2.
Hypertrophic scars are characterised by the over-expression of collagen, downregulated collagenase produc-
tion, heightened presence of fibroblasts, persistence of the myofibroblast phenotype, reduced apoptosis and
upregulation of pro-fibrotic mediators such as transforming growth factor-β (TGFβ)3,4. Fibroblasts are ac-
tivated to myofibroblasts under the action of TGFβ and mechanical tension, with myofibroblasts exhibiting
much greater traction than fibroblasts5. Dysregulation of myofibroblast activity and prolonged myofibroblast
activity generates contractures, leading to loss of organ function. Such tissue contractures are clearly visible
in skin hypertrophic scars that develop following burns, scleroderma and Dupuytren’s disease6. Additionally,
myofibroblast-generated contractures are intrinsically associated with organ fibrosis in the liver, heart, lung and
kidney7.
The poorly regulated collagen and collagenase synthesis intrinsic to hypertrophic scars are probably as-
sociated with over-stimulated fibroblasts and myofibroblasts, and are not causative factors. Consequently,
treatments that do not target these cells should not be expected to be as effective as therapies which aim to
address the stimulation and persistence of fibroblasts and myofibroblasts. The regulatory mechanism of the
fibroblast density is likely impaired by two key issues: the downregulation of apoptosis and the stimulatory
effects of TGFβ, both of which are considered in the present study.
In their study of mice dermal wound closure, Aarabi et al. 3 found that the application of mechanical tension
to a healing wound generated hypertrophic scarring, leading to an increase in cellularity and giving rise to a
four-fold decrease in cell apoptosis. They then clarified the importance of cell apoptosis in hypertrophic scarring
by examining p53-null mice, with consequent down-regulated cell apoptosis. In these experiments, significantly
greater scar hypertrophy and cellular density were observed. To further elucidate the link between hypertrophic
scars and small apoptotic rates, Aarabi et al. considered pro-apoptotic BclII-null mice, and found significantly
reduced scar hypertrophy and cellular density. Indeed, Linge et al. 8 found that while over 40% of fibroblasts
undergo apoptosis in contractile collagen, there was no detection of apoptosis in hypertrophic scar fibroblasts.
Moreover, Kose and Waseem 4 state that, while myofibroblasts of a normotrophic wound origin are usually more
sensitive than fibroblasts to apoptotic cues, the reverse is true in wounds healing with scar hypertrophy. Hence,
it is clear that down-regulated apoptosis is a key feature of hypertrophic scars.
Abnormal levels of TGFβ is associated with tissue fibrosis9. TGFβ is perhaps the key growth factor in
dermal repair, and is ubiquitous in the healing response. It is implicated in the stimulation of angiogenesis,
the formation of granulation tissue, the regulation of collagen synthesis and the development of fibroplasia1.
3It is known that the TGFβ isoforms TGFβ1 and TGFβ2 are strongly pro-fibrotic, with exogenous addition
to healing wounds giving rise to fibrotic scars10. However, the addition of TGFβ3 ameliorates the severity of
the final scar11. Thus, a treatment strategy that aims to block TGFβ1 and TGFβ2 or increase TGFβ3 should
prove effective in the treatment of pathological scars. Indeed, clinical trials on human subjects by Occleston
et al. 12 and Ferguson et al. 13 are showing promising results for the use of TGFβ3. They have found that early
addition of TGFβ3 to cutaneous wounds reduces early ECM deposition, improves the dermal architecture and
decreases subsequent scarring. Additionally, recent experimental results suggest that silicone sheeting may lessen
the appearance of hypertrophic scars by decreasing fibroblast contraction while simultaneously downregulating
TGFβ2
11.
The persistence of the myofibroblast phenotype is mediated by both reduced sensitivity to apoptotic cues
and up-regulated levels of TGFβ1 and TGFβ2. Greater availability of these isoforms of TGFβ implies that more
fibroblasts are activated to become myofibroblasts, and less apoptosis implies that myofibroblasts themselves
have a longer time to apoptotic death than their normal wound counterparts. Together, this suggests that the
important issue behind hypertrophic scars is the maintenance of the myofibroblast phenotype. Indeed, Wynn 14
states that myofibroblasts are “the key cellular mediator of fibrosis”.
Interestingly, targeting of myofibroblasts has been suggested as an anti-fibrogenic therapy for liver fibrosis15,
pulmonary fibrosis16, and as a potential anti-cancer therapy17. Drugs such as basic fibroblast growth factor
(bFGF), halofuginone and interferon, used in the treatment of pathological scarring in the dermis, may decrease
the presence of myofibroblasts by increasing the myofibroblast apoptotic rate or blocking activation of fibrob-
lasts to myofibroblasts2,17,18. However, this reduction in myofibroblast density appears to be incidental, with
researchers usually targeting collagen production or degradation. A treatment involving one or a combination
of factors that increases myofibroblast apoptosis should reduce the excessive contraction and aid resolution of
scar hypertrophy. We examine this idea in the subsequent sections.
Mathematical models are frequently formulated to investigate aspects of complex systems, such as dermal
wound repair, where components of the overall process can be considered in isolation and their effect upon
the whole elucidated (see Murphy et al. 19 and the references therein). In a sense this is not dissimilar from
in vitro experiments where elements of the whole system are extracted and explored. One such mathematical
investigation was undertaken by the authors in Murphy et al. 19 , where we developed a sophisticated model of
wound repair involving fibroblasts, myofibroblasts, TGFβ, collagen, strain and local forces. Where possible,
all parameter values in the model were taken from experimental investigations on human dermal repair. This
model is unique both in its description of tissue mechanics and in the representation of feedback between the
mechanics and fibroblast activation. This representation reproduces the contractile behaviour of acute wounds,
4modelling each phase of wound contraction. This repair description is an advance on previous models since
it does not require an artificial mechanism to induce permanent wound closure. In addition, the model was
validated against experimental data for rat dermal repair20 and, using realistic parameter values, the course of
adult human dermal repair. In each case the predictions were in good agreement with experimental observations.
Predictions from our model19 suggest that the roles of fibroblast activation, myofibroblast apoptosis and
TGFβ decay are critical in the repair of human dermal tissue. In each of these cases the model predicts increased
collagen density and excess contraction - with both the causative factors and resulting features indicative of
hypertrophic scar formation. This naturally poses the question of whether altering fibroblast activation, myofi-
broblast apoptosis or TGFβ decay could a) prevent scar hypertrophy, or b) reduce the extent of hypertrophic
scarring. This is the subject of the current paper; our main goal is to vary myofibroblast apoptosis and TGFβ
decay in our mathematical model to verify if altering these aspects could rescue normal repair.
Our approach is as follows. We pose a realistic range for expected wound contraction under normal repair
conditions. This is calculated by considering the minimum and maximum fraction of myofibroblasts expected
to undergo apoptosis (as determined from experimental results), which was found to accord with the normal
maximum bound of contraction of 30% expected for normal dermal repair. We then investigate changes in the
parameter values characterizing fibroblast activation, myofibroblast apoptosis and TGFβ decay. If contraction
returns or remains within the normal range, then we conclude that such an intervention may prevent hyper-
trophic scar formation. We also investigate different intervention times of one or two weeks following wounding
to ascertain if the timing of initiating treatment was important for the features investigated in the model.
As discussed in the following sections, we find that timing is an important factor when the myofibroblast
apoptotic rate is small, but not as important when the TGFβ decay rate is reduced. The different results are
an outcome of the subtle interactions between the different dependent variables involved in dermal repair in
this mathematical model and, as such, the timing, and indeed the extent to which myofibroblast apoptosis or
TGFβ decay needs to be altered to prevent scar hypertrophy, cannot be predicted a priori. That is to say, these
are not self-fulfilling features of the model but rather the outcome of the history-dependent interactions, and
the extent and timing of intervention.
METHODS
Here we give a summary of the Murphy et al. 19 paper, which describes an extension of the wound healing model
of Cook 21 by incorporating recently published experimental results in its chemical, cellular and mechanical
components. A distinctive attribute of the model (referred to as a morphoelastic model) is that strains are
5measured relative to a state in which the stress is zero. These are called effective strains. This approach is
useful for describing the mechanical evolution of biological tissue since plastic deformations normally associated
with growth and cellular remodelling are difficult to track mathematically, while the small deformations (the
effective strains) from the evolving zero stress state are amenable to simple linear viscoelastic theory.
The Murphy et al. model treats the wound and the surrounding skin as two separate compartments repre-
senting the wound space and the undamaged tissue, with the boundary between them (i.e. the wound edge)
free to move as healing progresses. The wound and its surroundings are a soft tissue that can move when
stresses are applied. These deformations are driven by fibroblasts and myofibroblasts (the activated phenotype
of fibroblasts) contracting collagen fibres and remodelling the local collagen network. As mentioned above, the
force balance equation that models the tissue comes from a morphoelastic framework (see Hall 22 for a detailed
description) with the tissue assumed to exhibit a viscoelastic response. It is this balance of the elastic and cell
traction forces inside and outside the wound that determine the movement of the wound boundary.
The remaining governing equations are in the form of conservation expressions for the cellular species, fi-
broblasts and myofibroblasts, the extracellular matrix, and the chemical mediator, TGFβ. Fibroblasts are
recruited from the surrounding dermis into the wound space where they proliferate and experience activation
to myofibroblasts. Together, fibroblasts and myofibroblasts produce collagen and are also involved in collagen
degradation. A feature of the paper is the incorporation into the model of the experimentally-observed depen-
dence of the activation of fibroblasts to their more contractile form, myofibroblasts, in the presence of TGFβ
in association with local tissue tension23. The model predictions compare well with experimental observations
on healing of wounds in rats by McGrath and Simon 20 .
The mathematical model itself involves six coupled ordinary differential equations with twenty-six dimension-
less parameters. The equations are solved numerically using standard routines of the mathematical programming
language MATLAB. Where possible, parameters are estimated using experimental data for adult human dermal
repair. For further details, see the Appendix.
RESULTS
We now use this model to consider wound intervention strategies to alleviate the development of a type of
pathological scarring known as a contracture, which is associated with excessive wound contraction. In order to
gauge the efficacy of treatments, a regime corresponding to normal wound contraction needs to be quantified. We
considered data from the paper by Moulin et al. 24 to estimate the parameter characterizing the myofibroblast
apoptotic rate, a. Moulin et al. were investigating the difference in myofibroblast apoptosis between normal skin
6wounds and cells from hypertrophic scars. Consequently, an accurate measurement of myofibroblast apoptosis
was critical. Furthermore, our paper concerns human dermal repair and Moulin et al. 24 considered cells from
human and not murine subjects (as is common in experimental investigations of dermal repair). Additionally,
we note that while Moulin’s experiments were conducted in vitro, we consider them to be more appropriate
than in vivo results taken from rat dermal repair.
Moulin et al. 24 obtained myofibroblasts from human dermal wounds after 12 days of repair. Pre-confluence
cell cultures between passages 3 and 6 were used, and apoptosis induced over a 24 − 72-hour period. Moulin
et al. 24 states that approximately 8−20% of human dermal myofibroblasts underwent apoptosis during this time.
We consider this range for myofibroblast apoptosis to be a characteristic feature of wound repair, and so use this
range in our model to predict the expected amount of contraction when 8%/day or 20%/day of myofibroblasts
undergo apoptosis, where an apoptotic rate of 8%/day (20%/day) will give the expected maximum (minimum)
amount of contraction. This corresponds to changing the rate parameter, a, in our model from 0.096 to 0.24 (see
the Appendix for details). We assume the same value for the parameter characterizing the rate of myofibroblast
apoptosis throughout the healing processes. Note that the rate at which myofibroblasts die is not constant but
depends on the density of myofibroblasts at that time, as described by the second term on the right-hand side
of equation (2) in the Appendix.
A myofibroblast apoptotic rate of 8%/day predicts wound contraction of approximately 30%. Farahani and
Kloth 25 state that under normal circumstances human dermal wounds heal with at most 30% contraction.
Hence, the maximum predicted contraction corresponds with that observed experimentally, and so we are
confident that this range for contraction reflects normal repair. This range of normal repair is represented in
each of the figures by a grey shaded area. We assume that a successful intervention strategy will be one that
ensures the final amount of contraction is within this normal range.
Disorder: Small Rate of Myofibroblast Apoptosis
A small apoptotic rate for myofibroblasts is associated with poor dermal repair3. Since myofibroblasts perform
the majority of wound contraction, persistence of this phenotype can lead to excessive contraction of the wound.
We investigate increasing the apoptotic rate of myofibroblasts and the resulting impact on wound contraction.
We choose to consider a normal apoptotic rate of 10%/day. Aarabi et al. 3 performed experiments to generate
hypertrophic-like scars in rats and found that there was a four-fold decrease in apoptosis within the hypertrophic-
like tissue. Thus, we assume that the same is true in human hypertrophic scars, and consider an untreated
apoptotic rate for myofibroblasts of 2.5%/day. This is consistent with experiments by Linge et al. 8 who found
that apoptosis for cells of a hypertrophic scar origin was virtually undetectable.
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Figure 1: Disorder: Small myofibroblast apoptotic rate. Intervention: Increase apoptotic rate after 8 days (early
intervention) or after 13 days (late intervention). The shaded region indicates the normal repair. Moulin et al. 24 gives
a range for the apoptotic rate of myofibroblasts of 8 − 20%/day. Simulations are run with minimum and maximum
apoptotic rates, allowing a normal range for wound contraction to be calculated. We chose to consider a normal rate
of 10%/day (i.e. a = 0.12). Aarabi et al. 3 found a four-fold decrease in apoptosis in hypertrophic scars. Hence, prior
to intervention and in the untreated case, we assume an apoptotic rate for myofibroblasts of 2.5%/day (i.e. a = 0.03).
When the intervention strategy is implemented, it increases the apoptotic rate to 10%/day. Increasing the apoptotic
rate to normal levels is able to rescue normal repair when effected early and significantly reduce the resulting predicted
wound contraction such that contraction is also within the normal limits of no more than 30%25.
Figure 1 gives the predictions for the movement of the wound boundary, with half the width of the wound
represented by L(t), and L(0) = L0. The shaded region in Figure 1 indicates the region of normal wound con-
traction predicted by our model. Curves below this region predict wounds that heal with excessive contraction,
indicating the formation of a contracture.
Two treatment times are considered: an early treatment effected at day 8 or a late therapeutic intervention
beginning on day 13. Comparing the predictions shows that strategies instituted at day 8 reduce the excessive
wound contraction more effectively than the same treatment applied from day 13. This indicates that the
therapy is more effective when implemented early. Increasing the apoptotic rate to normal levels is able to
rescue normal repair when effected early and significantly reduce the resulting predicted wound contraction
such that contraction is also within the normal limits of no more than 30%25.
While the model predicts that increasing the apoptotic rate to 10% per day restores a normal repair response
when the therapy is applied early, this is not the case when the treatment is applied after two weeks of repair.
When applied late, a more aggressive treatment is required to restore normal repair. These results suggest that
to restore normal repair, apoptosis must be returned to at least normal levels, with early intervention strategies
requiring less aggressive responses.
There are a number of methods to arrest myofibroblast development or induce myofibroblast apoptosis.
8Akasaka and colleagues have found that application of bFGF promotes apoptosis, reducing the presence of
myofibroblasts and thereby leading to a reduction in wound contraction26. Indeed, Tiede et al. 27 suggests
bFGF as a potential therapeutic agent for the treatment of hypertrophic scars and keloids. Mizuno et al. 16
found addition of hepatocyte growth factor induced matrix metalloproteinase (MMP) dependent apoptosis in
mouse lung fibrosis, reducing the advance of fibrotic tissue. Similar results have been obtained in dermal
tissue18. It has also been suggested that interferon, a potential drug for treatment of hypertrophic scars,
induces myofibroblast apoptosis2. Finally, Douglass et al. 15 found that using antibody targeting to increase liver
myofibroblast apoptosis is the most effective anti-fibrogenic therapy, promoting resolution of liver fibrosis. Thus,
given these experimental results and the predictions of our mathematical model, we suggest that specifically
targeting myofibroblast apoptosis in dermal pathologies should meet with similar success.
Disorder: Small TGFβ Decay Rate
The second disorder that we investigate is associated with a small decay rate of TGFβ. The size of the decay rate
is indicative of the length of the inflammatory response. It has long been argued that inflammatory mediators
such as TGFβ can cause pathological scarring, with acute or poorly regulated TGFβ associated with fibrosis10.
A small decay rate of TGFβ indicates a long inflammatory response, or poorly regulated activation of TGFβ.
Intervention: Neutralize TGFβ
We first investigate neutralizing TGFβ as a treatment strategy. By this we mean any method by which the
TGFβ pathway may be blocked, such as inhibiting activation or production of TGFβ, blocking TGFβ recep-
tor activation, blocking intracellular signalling or coactivator recruitment (for a full discussion see Varga and
Pasche 28 or Liu et al. 29).
There is discussion in the literature as to the timing of anti-TGFβ therapies. Numerous researchers have
recognised the importance of neutralizing TGFβ within the first 48 hours following injury10,12,30. However, we
chose to trial intervention strategies outside this timeframe, instead considering implementation at either day
8 or day 13 post wounding. Consequently, the interventions were applied to wounds presenting with evidence
of scar hypertrophy after one or two weeks of repair. As such, our results will not be directly comparable
with those of Shah et al. 30 , Ferguson and O’Kane 10 and Occleston et al. 12 . On the other hand, qualitative
comparison can be made with the experimental results of Lu et al. 31 . They found that early application of
TGFβ antibodies to rabbit wounds delayed wound repair with no reduction in scar hypertrophy when the wound
was treated on days 0, 2 and 4. However, the same antibody applied beginning during the second week of repair
post wounding (i.e. from day 7 to 13) induced a reduction in scar hypertrophy. Additionally, Ferguson and
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Figure 2: Disorder: Small TGFβ decay rate. The TGFβ decay rate is characterised by the parameter, b (see the
Appendix for details). Here we show the intervention of increasing the decay rate of TGFβ at day 8 (dotted curves) or
day 13 (dashed curves). Following intervention, the TGFβ decay rate is increased to its “normal” value. The black curves
represents the predicted response if no intervention strategy is implemented, while the dashed and dotted curves show
the predictions for healing following intervention. We again use the experimental data of Moulin et al. 24 to ascertain
the normal range of wound contraction (shaded grey).
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co-workers consider targeting particular isoforms of TGFβ, whereas Lu and colleagues applies an antibody that
neutralizes all TGFβ isoforms. As we are considering prevention of scar hypertrophy and a pan-neutralization
of TGFβ, we chose to compare with the experimental results of Lu et al. 31 , and initiate treatment on day 8 or
day 13.
To determine if normal repair is rescued, we consider the range of myofibroblast apoptotic rates described
by Moulin et al. 24 of 8 − 20%/day to be an intrinsic property in wound repair, and we use the normal decay
rate of TGFβ estimated from data obtained by Yang et al. 32 . This gives the shaded region in Figure 2. Curves
representing the wound boundary predicted to lie in this region are considered to indicate normal repair.
Figure 2 shows that in this case there is little difference between a treatment strategy begun at day 8 and one
implemented at day 13. Nonetheless, neutralizing or blocking the action of TGFβ essentially eliminates TGFβ
from the wound space following application of the treatment for 12 days. Consequently, by significantly reducing
the concentrations of TGFβ, there is a corresponding decrease in the activation of fibroblasts to myofibroblasts
(since differentiation is TGFβ-dependent). Indeed, it can be seen from Figure 2 that under this treatment
regime, we obtain “normal” repair. Hence, we predict that neutralizing TGFβ will significantly reduce wound
contraction through decreasing the presence of myofibroblasts and rescue normal repair. This is consistent with
the experimental findings of Lu et al. 31 in rabbits who found a reduction in scar hypertrophy when TGFβ
antibodies are injected into the lesion one week following wounding.
There are a number of proposed treatments that aim to block the TGFβ pathway, thereby acting as ther-
apeutic strategies for various disorders29. These interventions include blocking TGFβ production or activity,
blocking TGFβ receptor activation, blocking intracellular signal transduction or by blocking coactivator recruit-
ment28. Indeed, to the authors’ knowledge, of the drugs currently available that act with anti-TGFβ activity,
only Tranilast R© is being applied to hypertrophic scars and keloids with the view to reducing the appearance of
these scars28. Tranilast R© inhibits the synthesis of collagen in keloid fibroblasts by suppressing the secretion of
TGFβ from fibroblasts18.
Varying the ratio of the different TGFβ isoforms in the wound may also be a viable treatment strategy. The
isoforms TGFβ1 and TGFβ2 are known to be strongly pro-fibrotic, exacerbating the appearance of hypertrophic
scars and keloids. However, topical addition of TGFβ3 has been found to mediate the action of TGFβ1 and
TGFβ2 in acute wounds. Indeed, promising results are being obtained by Ferguson and O’Kane
10 and Occleston
et al. 12 for the prevention of scars, and the attainment of regenerative repair. One particular drug, avotermin R©,
which is essentially a delivery system for TGFβ3 is showing promising results in the treatment of acute wounds
in the human dermis12. This concept may yet also prove a potential curative strategy for hypertrophic scars
and keloids where heightened TGFβ1 is an issue. Indeed, therapies which aim to reduce TGFβ1 are currently
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being investigated as potential treatments for fibrotic scars18.
Finally, since inflammation persists until an epithelial cover is restored33, ensuring that there is rapid
reepithelialisation may mediate the effects of an exuberant inflammatory response or indeed, down-regulate
the inflammatory response itself. This may explain why the practice of transferring keratinocytes (the cells
responsible for reepithelialisation), and thereby covering the burn injury is critical to the healing of burn
injuries34.
Intervention: Increase Myofibroblast Apoptotic Rate
The decrease in contraction when TGFβ is neutralized is associated with the resulting reduction in myofibroblast
density. Therefore, it is proposed that increasing the death rate of myofibroblasts could also be an effective
method in the case where TGFβ persists.
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Figure 3: Disorder: Small TGFβ decay rate. Intervention: Increase the apoptotic rate of myofibroblasts on day 8 by a
factor of 4. While this intervention does not alleviate the formation of a pathological scar, it does attenuate the extent
of predicted contraction. Thus, scar severity has been reduced.
Figure 3 shows the predictions obtained when the rate of myofibroblast cell death is increased. While there is
a reduction in the predicted extent of contraction, this reduction is not sufficient to restore normal repair. Indeed,
the wound still heals with approximately 60% contraction, twice the maximum for normal repair. Therefore,
we predict that simply increasing myofibroblast apoptosis is not an effective treatment strategy when TGFβ
is poorly regulated. As mentioned above, TGFβ acts on the fibroblast population, increasing the activation of
fibroblasts to myofibroblasts. Increasing the myofibroblast apoptotic rate simply enhances the death rate of cells
once they have become myofibroblasts, but does not address the issue of continued and heightened activation of
fibroblasts to myofibroblasts. However, simply decreasing the sensitivity of fibroblasts to activation by TGFβ
is predicted to also prove ineffective as the key issue of continued and heightened presence of TGFβ would
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again be left unaddressed. This illustrates that the underlying cause for fibrotic scar development must be
addressed in order to rescue normal wound healing. While decreasing activation of fibroblasts to myofibroblasts
and increasing apoptosis of myofibroblasts will improve the resulting scar, TGFβ must be targeted if normal
repair is to be regained.
These ideas are consistent with observations by Phan 35 in lung tissue, and Chipev and Simon 36 in dermal
tissue, that TGFβ1 can actually afford protection against apoptosis
5. Thus, targeting of TGFβ or myofibroblast
apoptosis alone may not be enough, but rather a combination therapy that neutralizes TGFβ and induces
myofibroblast apoptosis may be required.
Interestingly, we note that in each instance, effective treatment strategies ensure that contraction terminates
within three weeks post injury. Figures 1 and 3 show cases where contraction is not terminated within this
time, and excessive contraction occurs. According to our model, once contraction stops, the healing response
has essentially terminated. Thus, the model predicts that early rescuing of normal repair in order to ensure
healing within three weeks post wounding is critical to preventing hypertrophic scar development. This result
is supported by clinical studies of burn injuries by Cubison et al. 37 who found that if wounds heal after the
three week point there is a significantly higher risk of hypertrophic scar development.
DISCUSSION
Our model predicts that targeting of TGFβ and decreasing the myofibroblast density are effective methods
to reduce or eliminate pathological scarring. On the basis of these findings, we suggest that development of
treatment modalities that target these aspects of repair will be the most effective in achieving normal repair
of wounds. Importantly, however, we also determine that early intervention is particularly important, in that
normal repair must be completed within the first three weeks post wounding. While our model suggests that
late interventions reduce the overall contraction predicted, the therapy is not nearly as effective as if it had been
implemented early. As noted above, this importance of timing is consistent with clinical studies by Cubison
et al. 37 who found that there is a link between the healing time of burn injuries and the development of
hypertrophic scars. In fact, Cubison et al. 37 confirmed that the three week point is an important predictor of
hypertrophic scar development, and that burns which take greater than three weeks to heal are at a significantly
higher risk of developing hypertrophic scars.
Since persistence of TGFβ, chronic inflammation and down-regulated apoptosis are associated with hyper-
trophic scar development33, and our model predicts that pathological scarring occurs under these circumstances,
it is possible that wounds which heal prior to the three week marker possess a normal or short inflammatory
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response and normal regulation of apoptosis, while wounds that require longer to heal have a prolonged inflam-
matory response and upregulated apoptosis. Indeed, Greenhalgh 33 states that healing of burns is prolonged
as a result of chronic inflammation. Additionally, in this instance, myofibroblasts overcompensate, leading to
severe scarring abnormalities33. These assertions are consistent with the predictions of our model. Therefore,
the further implications of this model should be reliable in that early treatment modalities which aim to reduce
inflammation or induce myofibroblast apoptosis should significantly improve the resulting scar and reduce the
appearance of hypertrophic scars and contractures.
Finally, since myofibroblast activation is enhanced by local skin tension, decreasing the tension across the
wound may reduce the myofibroblast population and therefore the risk of hypertrophic scar development. Deep
buried subcutaneous sutures diminish the tension around skin sutures, and many authorities advocate the use
of deep dermal sutures where possible38. The horizontal mattress stitch also reduces skin tension if the distance
between the wound edges is sufficient so as to spread the tension over a greater region with each stitch39. An
additional side effect of this technique may be to physically separate the local sources of tension and TGFβ.
Since fibroblasts require both tension and TGFβ to differentiate into myofibroblasts, stitching techniques such
as this may, by their very nature, prevent or significantly reduce myofibroblast development. However, care
must be taken as deep suture placement of contaminated wounds, even if thoroughly irrigated, may result in
increasing infection39.
In conclusion, we use mathematical modelling to predict that reducing the myofibroblast density and TGFβ
concentration within healing acute wounds will significantly improve the quality of the resulting scar, especially
if an intervention strategy is implemented early. We have also presented potential techniques for achieving
these aims, together with possible explanations for why these methods would be effective. We stress that these
predictions are based entirely on the outcomes from numerical simulations of our model and, as such, the
reliability of the conclusions is critically dependent upon how well the model captures true wound healing. We
acknowledge that the intention of this paper is to make more general hypotheses regarding possible intervention
strategies and that it does use a simplified mathematical representation of wound repair. In Murphy et al. 19 we
made a considerable effort to validate the model against experimental data, and the conclusions drawn in this
current work were also substantiated against current experimental results. Nonetheless, there are a number of
additional features that could be incorporated into our model in order to gain greater understanding of wound
closure, how treatment methods may work in vivo and to improve the model predictions; these include the effects
of spatial heterogeneity, wound geometry, angiogenesis and vascular remodelling, and sources of inflammatory
mediators other than fibroblasts or myofibroblasts. Indeed, the model would benefit greatly from an improved
representation of the inflammatory dynamics, which will allow greater interplay between the model’s species
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and an improved understanding of how changing the TGFβ concentration truly alters the course of repair.
Any spatial concerns require extending the model to a partial differential equation format, with the current
representation as the framework.
More generally, mathematics can function as the interactive microscope of biology, enabling the testing of
assertions regarding interactions between species, drugs, mechanics and more. In this paper we have sought to
illustrate how mathematics can be used to suggest the most appropriate timing for interventions in dermal wound
repair where either myofibroblasts or TGFβ are targeted. Further refinement of this model in conjunction with
experimental results could allow the development of a model in which we may observe the heterogeneous ingress
of cells into the wound space, growth factor secretion, construction of the extracellular matrix, angiogenesis,
the changing mechanical environment and investigate the impact on each of various intervention strategies. A
two or three-dimensional model would allow the impact of treatments such as pressure bandages and silicone
dressings to be evaluated, the incorporation of angiogenesis to verify how oxygen impacts wound closure, and
an improved representation of inflammatory kinetics could allow comparison between fetal and adult repair.
There is much insight to be gained from further collaboration between mathematicians and biologists, with
mathematics representing the future frontier of biology, and biology the future frontier of mathematics40.
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Summary of 2-Compartment Model
In this Appendix we summarise the 1-D non-dimensional mechanochemical description of dermal repair devel-
oped in Murphy et al. 19 . Parameters discussed here are the same as those used in that paper. The domain of
interest is divided into two regions, the wound space (from 0 < x < L) and the surrounding unwounded dermis
(from L < x < 1), where L is the wound boundary, x = 0 is the wound centre and x = 1 is a point far from the
wound site, representing an unwounded and undisturbed point. Within each region we consider an ordinary
differential equation in time for each species.
The model has eight independent variables: fibroblast density inside the wound, n; myofibroblast density in
the wound, m; collagen density within and without the wound, s and S; effective strain inside and outside the
lesion, e and E; the TGFβ concentration inside the wound, β; and the wound boundary location, L.
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Figure 4: Wound compartment diagram. The region 0 < x < L corresponds to half of the wound space while
L < x < 1 is the adjacent unwounded dermis, where x = 0 is the wound centre, x = L represents the wound
boundary and x = 1 is a point far from the wound site. We assume symmetry about the wound centre at x = 0.
The points x = 0 and x = 1 are fixed throughout the simulations, but the wound boundary at x = L(t) varies
with time. An increase (reduction) in L indicates wound retraction (contraction) as the wound boundary is
moving away from (towards) the wound centre, yielding an increase (decrease) in wound area. Species inside
the wound include fibroblasts (n), myofibroblasts (m), TGFβ (β), collagen (s) and strai, (e), while in the
undamaged tissue we have collagen (S) and strain (E), with the fibroblast density held constant at its density
in unwounded dermis. The movement of the wound boundary is determined by the force balance between the
internal (wound) and external (undamaged tissue) forces across x = L.
TGFβ (β)
Fibroblasts (n)
Growth
Diffusion
Myofibroblasts
(m)Activation
Apoptosis
Strain (e) Collagen (s)
Production
DegradationMechanics
Figure 5: Schematic of the interactions between the cellular, chemical and mechanical aspects considered in this
model. The corresponding variables are shown in parentheses. The factors that govern the local cellular density
are the solid curves, interactions that impact the collagen density are shown in dotted lines, while regulation
of strain and mechanics are shown in dash-dotted and dashed, respectively. This schematic describes the
interactions inside the wound space, for the corresponding diagram for unwounded dermis, ignore interactions
related to TGFβ and myofibroblasts.
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Fibroblasts inside the wound undergo logistic growth, are recruited in from the surrounding dermis, are
activated to become myofibroblasts under the action of TGFβ and elastic stress23, and experience advection as
the wound boundary moves. Outside the wound, fibroblasts are assumed to remain at their unwounded density.
Thus, fibroblasts satisfy the following equation
dn
dt
= n (1− n) + R(1− n)
L
− rY sβen− n
L
dL
dt
, (1)
where R, r and Y are positive parameters.
Myofibroblasts are activated from fibroblasts and undergo apoptosis24 and advection. Thus the governing
equation for myofibroblasts is given by
dm
dt
= rY sβen− am− m
L
dL
dt
, (2)
where a is a positive parameter that characterizes the death rate of myofibroblasts by apoptosis. We note that
myofibroblasts are assumed to be present in the developing scar but not in healthy dermis.
We assume there is an initial pool of growth factors within the wound established during the inflammatory
stage that simply decays with time. Hence, the TGFβ concentration in the wound can be modelled as
β(t) = exp (−bt) , (3)
where b is a positive parameter that characterizes the decay rate of TGFβ.
Collagen is synthesized by both fibroblasts and myofibroblasts. Each of these cell types also produce enzymes
that degrade the local collagen network. Thus, we assume collagen degradation is proportional to the cellular
densities. Collagen also undergoes advection. Hence, the collagen density inside and outside the wound satisfy
ds
dt
= κ(n+ ηm)(1− s)− s
L
dL
dt
, (4)
dS
dt
= κ(1− S) + S
1− L
dL
dt
, (5)
where κ and η are positive constants.
An increase in strain results when fibroblasts and myofibroblasts contract the local collagen fibres, and a
decrease in strain occurs due to cellular remodelling of the collagen network. Advection and tissue elasticity
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also affect the local strain. We consider the following form of the effective strain inside and outside the wound:
de
dt
= kζs(n+ pim)− kρ(n+ ηm)e
s
+
(1− e)
L
dL
dt
, (6)
dE
dt
= kζS − kρE
S
− (1− E)
1− L
dL
dt
, (7)
where kζ , pi, and kρ are positive constants.
The elastic and cell traction forces inside the wound must balance the same forces outside the wound. Thus,
Y se+ τ(n+ ζm)s = Y SE + τNS, (8)
where Y , τ and ζ are positive constants.
It is from the force balance equation that we generate an expression for the movement of the wound boundary
by differentiating (8) with respect to time and substituting (1)-(7); for full details see Murphy et al. 19 .
There are two key parameters in the model, a and b, where a characterizes the death rate of myofibroblasts
due to apoptosis, and is quantified by the percentage of myofibroblasts that undergo apoptosis over a 24-hour
period. Moulin et al. 24 estimates that 8− 20% of myofibroblasts undergo apoptosis over 24 hours. Hence, the
dimensional parameter a is given by the range a = 0.08−0.20/day. We typically consider a normal myofibroblast
apoptotic rate of a = 0.1/day.
The parameter b characterizes the decay rate of TGFβ, and was estimated from the exponential phase of
the data from Yang et al. 32 , representing the rate of reduction in TGFβ concentration per day. Curve fitting
was used to approximate this rate, giving b ≈ 0.354/day.
We then scaled the system relative to the proliferation rate of fibroblasts. Thus in our simulations, a and
b are given by a = 0.096 − 0.24, and b ≈ 0.4, with the typical myofibroblast apoptotic rate of a = 0.1/day
corresponding to a = 0.12 in our model. The other scaled parameter values in our model were κ = 0.27, τ = 2,
kζ = 0.0054, kρ = 0.54, Y = 71.3, R = 0.04, r = 0.22, ζ = 5, pi = 15 and η = 2.
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Figure 1: Disorder: Small myofibroblast apoptotic rate. Intervention: Increase apoptotic rate after 8 days (early
intervention) or after 13 days (late intervention). The shaded region indicates the normal repair. Moulin et al. 24 gives
a range for the apoptotic rate of myofibroblasts of 8 − 20%/day. Simulations are run with minimum and maximum
apoptotic rates, allowing a normal range for wound contraction to be calculated. We chose to consider a normal rate
of 10%/day (i.e. a = 0.12). Aarabi et al. 3 found a four-fold decrease in apoptosis in hypertrophic scars. Hence, prior
to intervention and in the untreated case, we assume an apoptotic rate for myofibroblasts of 2.5%/day (i.e. a = 0.03).
When the intervention strategy is implemented, it increases the apoptotic rate to 10%/day. Increasing the apoptotic
rate to normal levels is able to rescue normal repair when effected early and significantly reduce the resulting predicted
wound contraction such that contraction is also within the normal limits of no more than 30%25.
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Figure 2: Disorder: Small TGFβ decay rate. The TGFβ decay rate is characterised by the parameter, b (see the
Appendix for details). Here we show the intervention of increasing the decay rate of TGFβ at day 8 (blue curves) or
day 13 (red curves). Following intervention, the TGFβ decay rate is increased to its “normal” value. The black curves
represents the predicted response if no intervention strategy is implemented, while the red and blue curves show the
predictions for healing following intervention. We again use the experimental data of Moulin et al. 24 to ascertain the
normal range of wound contraction (shaded grey).
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Figure 3: Disorder: Small TGFβ decay rate. Intervention: Increase the apoptotic rate of myofibroblasts on day 8 by a
factor of 4. While this intervention does not alleviate the formation of a pathological scar, it does attenuate the extent
of predicted contraction. Thus, scar severity has been reduced.
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Figure 4: Wound compartment diagram. The region 0 < x < L corresponds to half of the wound space while
L < x < 1 is the adjacent unwounded dermis, where x = 0 is the wound centre, x = L represents the wound
boundary and x = 1 is a point far from the wound site, and is unaffected by the repair of the lesion. We
assume symmetry about the wound centre at x = 0. The points x = 0 and x = 1 are fixed throughout the
simulations, but the wound boundary at x = L(t) varies with time. An increase (reduction) in L indicates wound
retraction (contraction) as the wound boundary is moving away from (towards) the wound centre, yielding an
increase (decrease) in wound area. Species inside the wound include fibroblasts (n), myofibroblasts (m), TGFβ
(β), collagen (s) and strai, (e), while in the undamaged tissue we have collagen (S) and strain (E), with the
fibroblast density held constant at its density in unwounded dermis. The movement of the wound boundary is
determined by the force balance between the internal (wound) and external (undamaged tissue) forces across
x = L.
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Figure 5: Schematic of the interactions between the cellular, chemical and mechanical aspects considered in
this model. The corresponding variables are shown in parentheses. The factors that govern the local cellular
density are the solid curves, interactions that impact the collagen density are shown in dotted lines, while
regulation of strain and mechanics are shown in dash-dotted and dashed respectively. This schematic describes
the interactions inside the wound space, for the corresponding diagram for unwounded dermis, ignore interactions
related to TGFβ and myofibroblasts.
